Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370160 · ClinicalTrials.gov registry record · Phase 1
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
A Phase 1 study of Refractory B-Lineage Leukemia and Relapsed B-Lineage Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02370160 is a Phase 1 study of Refractory B-Lineage Leukemia and Relapsed B-Lineage Leukemia that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02370160, a Phase 1 study of Refractory B-Lineage Leukemia and Relapsed B-Lineage Leukemia, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but with a higher number of doses and a two-stage phase II extension component to confirm safety and make a preliminary determination of the activity level by disease using the dose identified in phase I.
Conditions Studied
Interventions
- BIOLOGICAL DT2219ARL
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2018-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370160
The ClinicalTrials.gov registry entry for NCT02370160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory B-Lineage Leukemia appearing as the primary indexed condition, and to 1 intervention - of which DT2219ARL is the first listed.
NCT02370160 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02370160 about?
NCT02370160 is a clinical study titled "HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma". This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but ...
What is the current status of trial NCT02370160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-12-21. Estimated completion is 2018-04-08.
What conditions does trial NCT02370160 study?
This clinical trial studies the following conditions: Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma.
What interventions are being tested in trial NCT02370160?
The interventions under investigation include: DT2219ARL (BIOLOGICAL).
Who is sponsoring clinical trial NCT02370160?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02370160 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.